Improvement In Skin Condition Research Articles

Phenylalanine Butyramide: A Butyrate Derivative as a Novel Inhibitor of Tyrosinase.

Metabolites resulting from the bacterial fermentation of dietary fibers, such as short-chain fatty acids, especially butyrate, play important roles in maintaining gut health and regulating various biological effects in the skin. However, butyrate is underutilized due to its unpleasant odor. To circumvent this organoleptic unfavorable property, phenylalanine butyramide (PBA), a butyrate precursor, has been synthesized and is currently available on the market. We evaluated the inhibition of mushroom tyrosinase by butyrate and PBA through in vitro assays, finding IC50 values of 34.7 mM and 120.3 mM, respectively. Docking calculations using a homology model of human tyrosinase identified a putative binding mode of PBA into the catalytic site. The anti-aging and anti-spot efficacy of topical PBA was evaluated in a randomized, double-blind, parallel-arm, placebo-controlled clinical trial involving 43 women affected by photo-damage. The results of this study showed that PBA significantly improved skin conditions compared to the placebo and was well tolerated. Specifically, PBA demonstrated strong skin depigmenting activity on both UV and brown spots (UV: -12.7% and -9.9%, Bs: -20.8% and -17.7% after 15 and 30 days, respectively, p < 0.001). Moreover, PBA brightened and lightened the skin (ITA°: +12% and 13% after 15 and 30 days, respectively, p < 0.001). Finally, PBA significantly improved skin elasticity (Ua/Uf: +12.4% and +32.3% after 15 and 30 days, respectively, p < 0.001) and firmness (Uf: -3.2% and -14.9% after 15 and 30 days, respectively, p < 0.01).

Metformin Therapy for Acne Vulgaris: A Meta-Analysis.

Acne vulgaris is a common disease, which occurs in adolescents as well as adults and has a significant influence on the patient's quality of life (QoL) in every aspect. Due to resistance to standard therapies, it has become necessary to prospect for new treatment strategies. It is important to highlight that the diagnosis and treatment of the underlying cause of acne such as metabolic and hormonal disorders may significantly improve the effectiveness of acne treatment. The correlation between Insulin Resistance (IR) and acne has been proven. Both disorders share many common occurrence factors and activation pathways. Metformin, an antihyperglycemic agent, seems to be a possible therapy option, not only because of its insulin sensitizing ability but also via plenty of additional effects of this medicine. While the efficiency of metformin therapy in patients with acne and Polycystic Ovary Syndrome (PCOS) is well explored, it is still necessary to evaluate it in patients without any endocrinopathies. This meta-analysis aimed to estimate the effectiveness of oral metformin as a monotherapy in acne patients without PCOS or other endocrinopathies. Study selection was performed with included criteria such as no PCOS and other endocrinopathies diagnosed, oral administration of metformin, and metformin in monotherapy. Selected studies contained comparisons in the Global Acne Grading System (GAGS) before and after metformin therapy. Statistical analysis detected significant improvement in skin condition after treatment with metformin.

Topical moisturizer with rose stem cell-derived exosomes (RSCEs) for recalcitrant seborrheic dermatitis: A case report with 6 months of follow-up.

Seborrheic dermatitis (SD) poses significant treatment challenges due to its chronic nature and the side effects associated with long-term use of conventional therapies like topical corticosteroids. In the search for alternative treatments, exosomes, particularly those derived from rose stem cells (RSCEs), offer a promising avenue due to their potential in managing chronic skin conditions. This case report examines the efficacy of a topical moisturizer containing RSCEs in treating a patient with refractory SD, aiming to provide an alternative treatment pathway. A 40-year-old male with a long-standing history of SD, unresponsive to traditional treatments, underwent a novel treatment regimen. This regimen included an initial topical application of 2.5 mL of RSCEs followed by a maintenance phase involving the application of a RSCE-containing moisturizer. Clinical outcomes were assessed through the Patient's Global Assessment (PGA) and Investigator's Global Assessment (IGA) scores, along with evaluations of scaling and erythema. Remarkable clinical improvement was noted as early as 1-day post-treatment, with significant reductions in redness, scaling, and itching. The patient experienced sustained relief throughout the 6-month follow-up, with a recurrence in the sixth month that was less severe than previous flare-ups. This demonstrated not only the efficacy of RSCEs in symptom management but also their potential in extending remission periods. The chronic management of SD can benefit from innovative treatments like the RSCE-containing moisturizer, as shown in this case report. While the observed outcomes are promising, indicating substantial improvements in skin condition and symptom management, larger controlled studies are necessary to validate the therapeutic potential of exosome-containing moisturizers fully. This case underscores the need for alternative therapies in SD treatment, highlighting the role of exosomes as a viable option.

TREATMENT OF SCABIOSIS AND TOXOCARIOSIS IN DOMESTIC CAT

Skin and digestive diseases are the most common problems encountered in cats. A six-month-old domestic cat with a body weight of 1.42 kg experienced problems with the skin and digestive system at the same time. Cases of cats complain that they often scratch and excrete worms when defecating, the feces are yellow and have a paste-like consistency. This research aims to determine the disease agent and intensity of infection that attacks cats so that appropriate treatment can be provided. On physical examination, alopecia, hyperkeratosis, crusting and scales were found on the head, bilateral ears, neck and elbow area. Supporting examinations carried out were skin examination using skin scraping, trichogram, cytological examination using the tape acetate method and otic swab with diffquick staining as well as fecal examination using the floating method and counting worm eggs using the Mc Master method. The diagnosis is confirmed based on the history, physical examination, and examination with results of scabiosis and toxocaryosis. The causative therapy used in this case was ivermectin (Ivomec®) injection at a dose of 300μg/kg BW subcutaneously given three times on days 0, 7 and 14 and pyrantel pamoate (Combantrin®) therapy at a dose of 25 mg/kg BW orally. Symptomatic therapy uses intramuscular injection of diphenhydramine HCl (2 mg/kg BW) and (chlorpeniramine maleate®) at a dose of 2 mg/head given 2x¼ orally given for three days, followed by supportive therapy given multivitamins and minerals (Caviplex®) given once a day orally for seven days. Topical therapy is given with sulfur soap to bathe cats at least once a week. The cat showed good progress starting from the third day, the level of pruritus decreased, then on the fourth day the cat did not expel worms from the anus and the stomach did not look as enlarged as when it was first examined, and on the sixth day it started to show hair growth, alopecia, crusting and hyperkeratosis began to decrease. After administering ivermectin the second time, the cat's case began to improve with the level of pruritus decreasing and the hair slowly growing. After the third injection, namely on the fourteenth day, the cat named Bolu was returned to its owner with improved skin condition and no longer scratching. Based on the history, physical examination and laboratory examination, the cat was given therapy by administering antihistamines, antiparasitics, worm medicine, as well as support by administering vitamins and topical use of sulfur soap. It is important for cat owners to consistently bathe their cats and give them regular deworming medication to prevent recurrent infections.

The therapeutic effects of ADSCs on photoaging of skin induced by UVB irradiation.

Skin photoaging affects appearance and is associated with a variety of skin diseases, even skin cancer. Therefore, the prevention and treatment of skin photoaging is very important. However, there is a lack of effective evaluation methods, so it is an urgent problem to explore a comprehensive, non-invasive and in vivo evaluation method. Adipose-derived mesenchymal stem cells (ADSCs) are widely used to improve skin conditions as easier to obtain and positive effects. Recently, as the development of ultrasound technology, skin ultrasound has been widely used. Changes in skin layer and structure can be observed by high-frequency ultrasound (HFUS). In addition, Shear wave elastography (SWE) technology can be used to monitor the change of skin hardness. However, it is necessary to further explore the ultrasound parameters in interpreting histological changes. We simulate the progression and treatment process of human skin photoaging by using UVB-induced nude mice skin photoaging model and ADSCs injection. The analysis of the degree and therapeutic effect of skin photoaging was conducted by HFUS, SWE and to verify with histopathology. Our study aims to clarify the value of HFUS combined SWE techniques in evaluating the degree and therapeutic efficacy of skin photoaging, which provides theoretical basis for diagnosis and treatment evaluation systems.

The Efficacy of a Cosmetic Preparation Containing Sheep Colostrum on Mature Skin: A Randomized Placebo-Controlled Double-Blind Study

Colostrum, the first milk produced by mammals, is rich in various bioactive components that provide numerous health benefits to newborns, such as growth factors, hormones, immunoglobulins, cytokines, and enzymes. Topical application of bovine or equine colostrum has been found to improve regeneration, accelerate cutaneous wound healing, and have moisturizing, protective, and anti-aging properties. The aim of this study was to examine the effect of a cosmetic preparation containing sheep colostrum on skin with signs of aging in mature women. Fifty-two women, aged 40–70, were randomized into two groups to receive either colostrum or placebo cream. The participants applied the cream for eight weeks. Skin hydration, TEWL, sebum, erythema, and tone were measured using a standardized Courage + Khazaka electronic GmbH Multi Probe Adapter; skin elasticity was measured with a cutometer, and images were taken by FotoMedicus. The treatment increased skin moisture, reduced TEWL, and improved skin firmness. These findings were confirmed by the subjective survey. The participants reported, inter alia, improved skin softness and less redness and hypersensitivity. Sheep colostrum cream was more effective at improving skin conditions than placebo cream. Colostrum creams can improve certain aspects of skin quality, especially the hydrolipid barrier, and overall rejuvenation.

High mobility group box 1 cytokine targeted topical delivery of resveratrol embedded nanoemulgel for the management of atopic dermatitis.

Resveratrol is a polyphenolic compound showing anti-inflammatory activity by inhibition of high mobility group box 1 cytokine responsible for the activation of nuclear factor-κB pathway in atopic dermatitis. To evaluate the efficacy of resveratrol through topical route we have developed resveratrol-loaded nanoemulgel for the effective management of atopic dermatitis in mice model. The resveratrol-loaded nanoemulsion (0.5%, 0.75% and 1% w/w) was optimized by spontaneous nano-emulsification. The optimized resveratrol-loaded nanoemulsions showed average globule size in the 180-230nm range and found to be monodispersed. The resveratrol nanoemulgel was prepared with a SEPINEO™ P 600 gel base and propylene glycol. Ex vivo permeation and retention study resulted in significantly higher skin retention of resveratrol from resveratrol-loaded nanoemulgel than free resveratrol-loaded gel. Preclinical efficacy of resveratrol nanoemulgel displayed promising therapeutic outcomes where, western blotting of skin tissues disclosed a significant reduction in the relative expression of high mobility group box 1, the receptor for advanced glycation end products, toll-like receptor-4 and phosphorylated nuclear factor-κB. Further, real-time polymerase chain reaction also disclosed a significant reduction in pro-inflammatory cytokines such as thymic stromal lymphopoietin, interleukin-4, interleukin-13, interleukin-31, tumor necrosis factor-α and interleukin-6. The histopathological examination of skin sections showed improvement in the skin condition. Collectively, the findings from our study showcased the significant improvement in the atopic dermatitis skin condition in mice model after topical application of resveratrol loaded nanoemulgel.

Ultrasonographic Picture Of The Skin And Subcutaneous Tissue In The Treatment Of Cellulite Using The Compressive Microvibration®

In recent years, the demand for non-invasive methodologies in aesthetic medicine for treating localized adiposity, cellulite, and sagging skin has increased significantly, particularly the demand for massage techniques with mechanical vibrations. The aim of the present study is to evaluate the effectiveness of Compressive Microvibration® in reducing the expression of cellulite and improving skin conditions in women of different ages under ultrasound control during 60 days of observation. A prospective, single-center, nonrandomized study enrolled 27 women with mild to moderate gynoid lipodystrophy, aged 40 to 69 years, who have been subject to twelve sessions of Compressive Microvibration® (Endospheres®). A specialized high-resolution digital ultrasound system, the DUB SkinScanner (tpm GmbH, Germany), has been used to visualize the skin. Also, the sample anthropometric parameters have been measured, the body mass index has been calculated, and photographs have been taken. In the patients included in the study, in all age groups, after complete treatment of Endospheres®, a decrease in BM has been noted, with a reduction of the bitrochanteric and hip circumference. An improvement in the morphological topography of the skin in terms of regularization of skin irregularities, leveling of reliefs, reduction of depressions, and increase in skin elasticity and density has also been recorded. After a cycle of therapy on the anterior surface of the abdomen and the thigh anterior and posterior surfaces, the scannograms revealed a decrease in the thickness of the epidermis at various levels, the resolution of the phenomenon of hyperkeratosis, a compaction of the dermis, and an increase in its homogeneity and echogenicity. The effect obtained was still present during a control examination two months after the conclusion of the treatment. The analysis of the dynamics of ultrasound criteria demonstrated the effectiveness of the Compressive Microvibration® in women with mild to moderate gynoid lipodystrophy to improve their skin conditions and maintain the obtained effect for 2 months of observation without unwanted side complications.

Safety and efficacy of whole-body chlorhexidine gluconate cleansing with or without emollient in hospitalised neonates (NeoCHG): a multicentre, randomised, open-label, factorial pilot trial

Healthcare-associated infections account for substantial neonatal in-hospital mortality. Chlorhexidine gluconate (CHG) whole body skin application could reduce sepsis by lowering bacterial colonisation density, although safety and optimal application regimen is unclear. Emollients, including sunflower oil, may independently improve skin condition, thereby reducing sepsis. We aimed to inform which concentration and frequency of CHG, with or without emollient, would best balance safety and the surrogate marker of efficacy of reduction in bacterial colonisation, to be taken forward in a future pragmatic trial evaluating clinical outcomes of sepsis and mortality. In this multicentre, randomised, open-label, factorial pilot trial, neonates in two hospital sites (South Africa, Bangladesh) aged 1-6 days with gestational age ≥ 28 weeks and birthweight 1000-1999 g were randomly assigned in a factorial design stratified by site to three different concentrations of CHG (0.5%, 1%, and 2%), with or without emollient (sunflower oil) applied on working days vs alternate working days. A control arm received neither product. Caregivers were unblinded although laboratory staff were blinded to randomisation Co-primary outcomes were safety (change in neonatal skin condition score incorporating dryness, erythema, and skin breakdown) and efficacy in reducing bacterial colonisation density (change in total skin bacterial log10CFU from randomisation to day-3 and day-8). The trial is registered at the ISRCTN registry, ISRCTN69836999. Between Apr 12 2021 and Jan 18 2022, 208 infants were randomised and 198 were included in the final analysis. Skin condition scores were low with mean 0.1 (sd=0.3; N=208) at baseline, 0.1 (sd=0.3; N=199) at day 3 and 0.1 (sd=0.3; N=189) at day 8, with no evidence of differences between concentration (1% CHG vs 0.5% estimate=-0.3, 95% CI= (-1.2, 0.6), p=0.55. 2% CHG vs 0.5% CHG estimate=0.5 (-0.4, 1.4), p=0.30), increasing frequency (estimate=-0.4; 95% CI= (-1.1, 0.4), p=0.33), emollient (estimate=-0.5, (-1.2, 0.3), p=0.23) or with control (estimate=-0.9, (-2.3, 0.4), p=0.18). Mean log10CFU was 4.9 (sd=3.0; N=208) at baseline, 6.3 (sd=3.1; N=198) at day 3 and 8.4 (sd=2.6; N=183) with no evidence of differences between concentration (1% CHG vs 0.5% estimate=-0.4; 95% CI= (-1.1, 0.23); p=0.23. 2% CHG vs 0.5% CHG estimate=0.0 (-0.6, 0.6), p=0.96), with increasing frequency (estimate=-0.4; 95% CI= (-0.9, 0.2); p=0.17), with emollient (estimate=0.4, 95% CI= (-0.2, 0.9); p=0.18) or with control (estimate=-0.2, 95% CI= (-1.3, 0.9); p=0.73). By day-8, overall 158/183 (86%) of neonates were colonised with Enterobacterales, and 72/183 (39%) and 69/183 (9%) with Klebsiella spp resistant to third-generation cephalosporin and carbapenems, respectively. There were no CHG-related SAEs, emollient-related SAEs, grade 3 or 4 skin scores or grade 3 or 4 hypothermias. In this pilot trial of CHG with or without sunflower oil, no safety issues were identified, and further trials examining clinical outcomes are warranted. The relatively late start application of emollient, at a mean of 3.8 days of life, may have reduced the impact of the intervention although no subgroup effects were detected. There was no clear evidence in favour of a specific concentration of chlorhexidine, and there was rapid colonisation with Enterobacterales with frequent antimicrobial resistance, regardless of skin application regimen. The MRC Joint Applied Global Health award, the Global Antibiotic Research and Development Partnership (GARDP), MRC Clinical Trials Unit core funding (UKRI) and St. George's, University of London.

Magnesium of Dead Sea Salts as a Key Factor for the Treatment of Seborrheic and Atopic Dermatitis: A Case Report

Background: Seborrheic and atopic dermatitis are common and chronic inflammatory skin diseases. Conventional treatments are often ineffective and can have significant side effects. Magnesium dead sea salt has a high concentration of magnesium, and previous research shows its potential to help improve skin conditions.&#x0D; Case presentation: Patients with chronic seborrheic and atopic dermatitis were treated with topical 5% dead sea salt magnesium for 4 days. Patients experienced significant improvement in their symptoms.&#x0D; Conclusion. Dead Sea salt magnesium can be a safe and effective treatment for seborrheic and atopic dermatitis.

Improvement of postural control in the frail older adults through foot care: A pre- and post-intervention study

Frailty in older adults often leads to foot issues, increasing fall-related fracture risk. Mechanoreceptors, the pressure receptors in the foot sole, are pivotal for postural control. Foot problems can impair mechanoreceptor function, compromising balance. This study aimed to examine the effect of foot care on postural control in frail older adults. Forty-eight participants underwent a five-month monthly foot care intervention. Measurements were taken before and after this intervention. Participants stood for 45 s in a static, open-eyed position on a stabilometer. Center-of-pressure (CoP) analysis included total trajectory length, integrated triangle area, rectangular area, and range of motion in anterior–posterior and medio-lateral directions. Results indicated that foot care significantly increased toe ground contact area by 1.3 times and improved anterior–posterior motion control during static standing. Enhanced postural control resulted from improved skin condition due to foot care that intensified mechanoreceptor signal input and improved postural control output. These findings underscore the potential for reducing fracture risks in older adults through proactive foot care. The study highlights the vital role of foot care in enhancing postural control, with broader implications for aging population well-being and safety.

A multidisciplinary approach to managing lymphorroea in primary lymphoedema: a case study.

This case study describes the successful management of a patient with primary lymphoedema, who was experiencing lymphorrhoea and epidermolysis, using a multidisciplinary approach. The patient had Klippel-Trenaunay syndrome. The multidisciplinary team, in an outpatient clinic in Japan, included a certified lymphoedema therapist, plastic surgeons, and a wound, ostomy and continence nurse. The team performed complex physical therapy and lymphaticovenular anastomosis, which promoted the resolution of the lymphorrhoea. This resulted in improvements in skin condition, the prevention of recurrent cellulitis, and no increase in limb circumferences during the 1-year follow-up period. This report highlights the importance of a multidisciplinary approach to lymphoedema management, including lymphorrhoea control that fitted in with the patient's daily life. It is hoped that this article will contribute to the improvement of the quality of life of patients with lymphoedema.

513 - Blockage of IL-25 pathway as a potential target therapy for atopic dermatitis

Abstract Introduction Interleukin 25 (IL-25) is an alarmin that binds to its receptor composed of IL-17RA and IL-17RB and is known to induce the production of type 2 cytokines, leading to T helper type 2 (Th2) inflammatory responses. Atopic dermatitis (AD) is an autoimmune and chronic disorder that causes inflammation, dryness, redness and irritation of the skin. It is well-­documented that upregulated IL-25 expression is tightly correlated with the disease severity of AD patients, suggesting that the IL-25 pathway is a potential therapeutic target of AD. SM17 is a humanized antibody of the IgG4/kappa isotype targeting the IL-25 pathway via specific binding to IL-17RB, a co-receptor for IL-25 expressed on the surface of ILC2 cells, dendritic Cells, fibroblast and epithelial cells. Therefore, we hypothesize that SM17 might serve as a potential therapeutic treatment for AD. Objectives The current study aims at investigating if blockage of IL-25 pathway through SM17 administration could ameliorate AD associated inflammation, skin pathology and pruritus. Methods To provide first evidence that SM17 could improve skin conditions, PBMCs from healthy individuals were pretreated with a cocktail of alarmins comprising IL-25, IL-33, and TSLP with or without SM17, and the mixture was co-cultured with the fully differentiated human keratinocyte cell line HaCaT in a transwell system for five days. Filaggrin level in HaCaT cells was used as an indicator for skin health. Beneficial effects of SM17 in AD was further tested in the 1-Fluoro-2,4-dinitrobenzene (DNFB) induced AD mouse model. DNFB and SM17 were administrated to the animals once per week and tissues were harvested after a month. Single cells were isolated from submental lymph nodes for ex-vivo culture while both dorsal skin and ear were collected for histological and biochemical analyses. In vivo efficacy of SM17 was further compared with upadacitinib, a JAK1 inhibitor currently approved by the FDA for the treatments of adults and adolescents aged 12+ years with moderate to severe AD, via behavioral, histological and biochemical analyses. Results We first demonstrated that SM17 could potentially ameliorate the skin condition by upregulating the filaggrin levels in keratinocyte during Th2 inflammatory responses in vitro. In the DNFB induced AD mouse model, SM17 could improve the skin conditions in both ear and dorsal skin through attenuation of Th2 cytokine levels in submental lymph node and skin samples, and reduce infiltration of mast cell and eosinophil, while upregulating filaggrin expression in the skin layer. Weekly administration of SM17 provided similar efficacy as upadacitinib (5 doses/week) to suppress DNFB induced scratching behavior, thickening of skin and ear, and global induction of Th2 inflammatory responses in multiple tissues. Conclusions In summary, these in vitro and in vivo data indicate that blockade of IL-25 pathway by SM17 could suppress Th2 mediated inflammatory response and ameliorate the AD pathology similar to that of upadacitinib, probably with a superior safety profile as demonstrated in our Phase I clinical trial (ClinicalTrials.gov Identifier: NCT05332834), where good safety profile and tolerability were observed with no reported cases of severe TEAE. We believe that SM17 could serve as a potential therapeutic treatment for AD in the future.

Theacrine enhances autophagy and inhibits inflammation via regulating SIRT3/FOXO3a/Parkin pathway.

Psoriasis, a common chronic inflammatory skin condition, impacts around 2%-3% of the global population. Theacrine is recognized for its potential anti-inflammatory and antioxidant properties. However, the role of theacrine in psoriasis remains unclear. To investigate the effects of theacrine on psoriasis and explore the underlying signaling pathways. For imiquimod (IMQ)-induced Psoriasis-like mice, the psoriatic inflammation was monitored using Psoriasis Area and Severity Index (PASI). The skin damage was observed using Hematoxylin and Eosin staining. The KI67 and CD4 in skin tissues were assessed using Immunohistochemistry analysis. Western blots were performed to evaluate the expression of Keratin 1 (KRT1), KRT6, LC3, P62, Beclin1, T-bet, GATA3, RAR-related orphan receptor (ROR)-γt, Sirtuin-3 (SIRT3), Forkhead Box O3a (FOXO3a) and Parkin. Additionally, LC3B expression was analyzed using an immunofluorescent assay, while flow cytometry was performed to analyze the percentage of Th17, Th1, and Th2 positive cells in skin-draining lymph node. Theacrine improved skin condition by reducing hyperkeratosis and acanthosis, lowering PASI scores, and decreasing KI67-positive cells. Theacrine also modulated keratin expression, elevating KRT1 while reducing KRT6 levels. Theacrine enhanced autophagy indicated by an increased LC3-II/LC3-I ratio and Beclin1, while reduced P62 levels. Additionally, Theacrine reduced CD4-positive cells and suppressed Th17 and Th1 cell activation. Theacrine activated the FOXO3a/Parkin pathway by upregulating SIRT3 expression, and down-regulation of SIRT3 counteracted theacrine's effects in psoriasis-like mice. Theacrine inhibits skin damage, promotes autophagy, and mediates inflammation in IMQ-induced psoriasis mice via upregulating SIRT3 to activate FOXO3a/Parkin pathway, positioning theacrine as a candidate for psoriasis treatment.

P1002 De novo and drug-induced skin manifestations in Inflammatory Bowel Disease patients: The impact of anti-tumour necrosis factor therapy

Abstract Background Skin disorders in inflammatory bowel disease (IBD) consist of extra-intestinal manifestations (EIM) or drug-induced lesions. This study explores de novo skin lesions and the emergence of immune-mediated skin disorders induced by anti-tumour necrosis factor (anti-TNF) agents. Methods Patients with EIMs, de novo skin lesions, and drug-induced skin eruptions were identified from an IBD patient database on advanced therapies. Data on time intervals from the initiation of IBD treatment to the development of skin disorders, causative agents, and subsequent management were collected. Results In a cohort of 1,773 patients (993 with ulcerative colitis, 746 with Crohn’s disease, and 31 with IBD unclassified), 30% (549) exhibited skin manifestations, with 28% (491 cases) showing de novo skin conditions. Identified skin manifestations included psoriasis/psoriasiform rash (18.3%), eczema (16.3%), seborrheic dermatosis (13.8%), acne (9.8%), actinic keratosis (5.3%), rosacea (4.7%), erythema nodosum (EN, 3.5%), cutaneous Crohn's disease (CCD, 2.6%), folliculitis (1.8%), pyoderma gangrenosum (PG, 1.5%), and others. Of the skin lesions, 31.8% (175) occurred before the IBD diagnosis, with a median duration of 8 years, while 51.9% (286) developed post-diagnosis unrelated to therapies. Biologic therapies improved extraintestinal skin lesions in 19 patients (3.4%). Notably, all 3 EN cases and 4 out of 5 PG cases achieved full resolution with biological treatments, leading to improved IBD activity. Similarly, 9 out of 10 Crohn’s disease patients with CCD showed improved skin conditions following biological treatments Fifty-eight patients (3.3%) experienced drug-induced skin lesions, with a median age at IBD diagnosis of 35 years (ranging from 17 to 67). The majority (91.3%) of cases were attributed to anti-TNF agents, and psoriasiform lesions were the most prevalent (60.3%). The median duration from treatment initiation to the onset of drug-induced skin lesions was 23 months (ranging from 0 to 115 months). Among the affected individuals, 19 using originator anti-TNF agents developed skin lesions, with 13 having psoriatic lesions. In comparison, 34 patients on biosimilar anti-TNF agents developed skin lesions, and 23 of them had psoriatic lesions. The progression of skin lesions led to anti-TNF discontinuation in 33 patients, of whom 25 transitioned to Vedolizumab or Ustekinumab. Resolution occurred in 22 patients. Conclusion Anti-TNF-induced skin lesions, notably psoriasiform lesions, appear to be more prevalent in the biosimilar era among IBD patients, often leading to discontinuation. Nevertheless, resolution is possible through strategic switches to alternative biologic agents.

Cutibacterium improves skin condition.

Cutibacterium improves skin condition.

Impact of heliotherapy and phototherapy on the course of atopic dermatitis

Introduction and purpose. Atopic dermatitis (AD) is a common chronic inflammatory skin disease that affects many children and adults around the world. It has been also empirically known that some environmental factors such as exposure to the sun can be beneficial for patients with AD. The purpose of this literature review is to present positive impact, as well as challenges and risks of heliotherapy and phototherapy on patients suffering from AD.&#x0D; Material and methods. The article is a review of publications obtained from the PubMed database and published between 2017-2023. Based on the keywords "phototherapy" "heliotherapy"and "atopic dermatitis", 14 articles were selected. Finally, 1 meta-analysis and 3 observational studies were included in the rewiev.&#x0D; Brief description of the state of knowledge. People with AD have a compromised skin barrier, which favors infiltration by activated Th2 cells, and their cytokine, causing thickening of the skin. It makes management of AD challenging. It is known that most patients’ skin condition improves due to sun exposure. This is why an artificial UV radiation (UVR) is employed for the treatment. The idea is to administrate a non-ionizing radiation to the skin. Both sunlight and artificial light have a significant immunosuppressive effect on the skin.&#x0D; Summary. Phototherapy as well as heliotherapy improved skin condition of people suffering from AD. It was appreciable by the end of few weeks of studies and also afer 3 months, reflected by improvement in PO-SCORAD, VAS and DLQI scales. During some of the studies there have been incidents of side-effects. More research is necessary to define a long-term effect of this kind of treatment and the role of chronic and prolonged therapy of AD.

Efficacy of treatment of small animals with triamcinolone-based medications for atopic dermatitis

Among the diseases of small pets, skin diseases are one of the leading ones. Atopic dermatitis is a common skin condition in small pets, which, according to veterinarians’ estimates, affects 10-15% of dogs and 7-18% of cats. Depending on the allergens involved, clinical signs can be seasonal or non-seasonal, and the disease usually requires lifelong treatment. The purpose of this study was to investigate the therapeutic efficacy of treating atopy in dogs and cats with the use of triamcinolone-based veterinary medications (oral suspension). Standard clinical, haematological, biochemical, and immunological methods were used in the study. The increased content of total immunoglobulin E (Ig E) in the blood of experimental animals before treatment (Group I – 3.4 times, and Group II – 3.9 times compared to the control) indicates the presence of an allergic response in the body. It was found that the tested veterinary medications do not substantially affect the haematological parameters of dogs and cats when administered orally, and in therapeutic doses do not have a toxic effect on the functional state of the liver and kidneys. It was proved that on Day 4 of use of oral suspension No. 1 and No. 2 based on triamcinolone (1%) acetonide and a complex of B vitamins in a therapeutic dosage, an improvement in the general clinical condition of animals was recorded. On Day 8 of treatment, dogs and cats in experimental Groups I and II showed improvement in skin condition: a reduction in the lesion area, absence of redness, scratching, and exfoliation. The general clinical condition of the skin of the experimental animals stayed unchanged from Day 8 to Day 12. The developed oral suspensions have a pronounced anti-allergic effect and improve the skin condition of small pets (dogs and cats) with atopic dermatitis

A narrative review of fixed combination calcipotriol/betamethasone aerosol foam (Enstilar®) in the management of psoriasis with scalp involvement.

The scalp is the most common site affected in patients with psoriasis with up to 80% of these patients having some degree of scalp involvement. In this narrative review, we evaluate available data on the use of an innovative aerosol foam formulation of calcipotriol plus betamethasone dipropionate (Cal/BD) to treat patients with psoriasis and scalp involvement. The full PubMed database was searched using the terms "calcipotriol", "betamethasone dipropionate" and "aerosol foam", and all articles relating to "psoriasis with scalp involvement" were retrieved and used in the preparation of this review. The evidence supporting the clinical effectiveness, tolerability and impact on health outcomes of Cal/BD aerosol foam in patients with scalp psoriasis was obtained from a phase II clinical trial and real-world evidence data from a non-interventional study as well as from two case series. The findings from these studies show that Cal/BD aerosol foam is rapidly effective, improves skin condition, alleviates symptoms such as itch, and has a positive impact on patient quality of life. These attributes address several unmet needs for patients with psoriasis with scalp involvement and have the potential to improve individual adherence to treatment.

Влияние дроспиренонсодержащего контрацептива на состояние кожи у женщин с регулярным менструальным циклом

Background: combined oral contraceptives (COCs) are one of the most popular methods of contraception. Apart from pregnancy prevention, it has proven other positive non-contraceptive effects. However, there are cases of acne vulgaris (AV) manifestation during COCs intake or its course worsens, which can lead to treatment refusing. Aim: to study the COCs effect (20 μg ethinyl estradiol (EE) and 3 mg drospirenone (DRSP)) on the skin condition of young women with a regular menstrual period. Patients and Methods: a prospective study was performed, which included 18 female patients of reproductive age (mean age 20.67±0.46 y.o.) with a regular menstrual period who sought medical advice to select a contraceptive. Of these, 11 had mild to moderate AV manifestations. The female patients were recommended to take DRSP-containing COConce daily before bedtime from the 1st day of the menstrual period for 28 straight days (1 period) — a total of 6 periods. Before the treatment initiation, as well as 3 and 6 months after the COCs intake start, the skin condition and indicators of the Acne-specific Quality of Life Questionnaire (Acne-QoL) of female patients with AV were evaluated. Results: the number of female patients without AV or with improvement after 3 and 6 months of treatment was 12 (66.67%) and 18 (100%), respectively. Compared with the baseline, there was a statistically significant decrease in Acne-QoL from 68 (63-80) to 40 (36-50) and 5 (10- 17) after 3 and 6 months, respectively (p&lt;0.05). The good tolerability of DRSP-containing COC was also noted. Adverse events that were independently eliminated and did not require drug withdrawal were recorded in two (11.1%) cases. Conclusion: the use of DRSP-containing COC (20 μg EE and 3 mg DRSP) in women with a regular menstrual period improves skin condition (reduces the amount and severity of AV) and reduces Acne-QoL. KEYWORDS: acne, drospirenone, ethinyl estradiol, reproductive period, regular menstrual period, acne vulgaris, questionnaire, quality of life. FOR CITATION: Saprykina L.V., Narimanova M.R. Drospirenone-containing contraceptive effect on the skin condition in women with a regular menstrual period. Russian Journal of Woman and Child Health. 2024;7(1):41–44 (in Russ.). DOI: 10.32364/2618-8430-2024-7-1-6.